Hybrigenics hires head of corporate and business development

William Vickery joins firm from ExonHit

Hybrigenics, a French bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialised in protein interactions services, has appointed William Vickery to the newly created position of head of corporate and business development.

Vickery was for five years senior director of business development at ExonHit.

Prior to joining ExonHit Therapeutics in 2006 and since 2003, he was business development director of Roche Pharmaceuticals in the US, where he was responsible for out-licensing and divestiture of Roche-developed assets.

‘I am very excited about joining Hybrigenics and look forward to helping the company establish strong partnerships to develop breakthrough therapeutics to treat cancers and other diseases,’ said Vickery.

You may also like

Research & Development

Hybrigenics and Servier sign three-year research deal

Will study deubiquitinating enzymes (DUBs) applied to a number of therapeutic areas
Ingredients

Hybrigenics develops new oral formulations of inecalcitol

New capsules are more concentrated in inecalcitol and contain a fixed 2mg amount that will be more convenient, with a maximum of two small capsules to swallow, which also favours compliance
Ingredients

Hybrigenics improves inecalcitol synthesis

French firm makes patent application for high-yield inecalcitol production
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development

Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia

AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
Pharmaceutical

Boehringer Ingelheim adds antibody-based cancer drug from AimedBio to its portfolio

The two have signed a licence agreement, which will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with the new asset expected to enter first-in-human studies next year
Subscribe now